Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%. The move reads as company-specific strength rather than a broad risk-on tape, with market breadth on
* Shares of Iovance Biotherapeutics rise 27.5% to $14, their highest level in more than two years * Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln * "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue
Iovance raised full year 2026 revenue guidance to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Proleukin.Key Highlights:Original SEC Filing: IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifyi…
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 MillionStrong U.S. Demand for Amtagvi and Proleukin Drives Increased OutlookPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. NASDAQ:IOVA, a commercial biotechnology…
Iovance Biotherapeutics lifted full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong U.S. demand for Amtagvi and Proleukin. Second-quarter 2026 total product revenue hit a record $99.3 million.
IOVA - Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million